https://orcid.org/0000-0002-0951-3203
References
- Andrew P, Jeffrey P, Roberts S, Walker D, Weaver R. 2001. The Drug Metabolism Discussion Group in 2001. Xenobiotica. 31(8–9):457–458.
- Brady K. 2011. The Drug Metabolism Discussion Group in 2011. Xenobiotica. 41(8):603–604.
- Beaumont K, Pike A, Davies M, Savoca A, Vasalou C, Harlfinger S, Ramsden D, Ferguson D, Hariparsad Nm Jones O, McGinnity D. 2023. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs). Xenobiotica. in Press.
- Berlo D, Van de Steeg E, Amirabadi H, Masereeuw R. 2021. The potential of multi-organ-on-chip models for assessment of drug disposition as alternative to animal testing. Curr Opin Toxicol. 27:8–17.
- Chen E, Bondi R, Michalski P. 2021. Model-based Target Pharmacology Assessment (mTPA): an approach using PBPK/PD modeling and machine learning to design medicinal chemistry and DMPK strategies in early drug discovery. J Med Chem. 64(6):3185–3196.
- Franklin RA, Vose CW, Wiltshire H. 1992. The Drug Metabolism Discussion Group 1991. Xenobiotica. 22(7):733–734.
- Fromson JM, Allen JG, Franklin RA, Neal MG, Harnby G. 1981. The Drug Metabolism Discussion Group. Xenobiotica. 11(12):801–801.
- Géhin C, Holman S. 2021. Advances in high-resolution mass spectrometry applied to pharmaceuticals in 2020: a whole new age of information. Anal Sci Adv. 2(3–4):142–156.
- Glassman PM, Balthasar JP. 2019. Physiologically-based modelling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab Pharmacokinet. 34(1):3–13.
- Hood S, Kenworthy D, Christensen JK. 2022. Meeting report: oligonucleotide ADME workshop. Xenobiotica. 1–5. in Press.
- Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. 2022. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective. Pharm Res. 39(8):1701–1731.
- Mullard A. 2021. 2020 FDA drug approvals. Nat Rev Drug Discov. 20(2):85–90.
- Rose RH, Sepp A, Stader F, Gill Kl Liu C, Gardner I. 2023. Application of physiologically-based pharmacokinetic models for therapeutic proteins and other novel modalities. Xenobiotica. in Press.
- Sonesson A, Brady K, Bjørnsdottir I, Christensen JK. 2021a. Meeting report: 1st workshop of the peptide ADME Discussion Group. Xenobiotica. 51(1):122–125.
- Sonesson A, Bjørnsdottir I, Christensen JK, Kammersgaard Christensen J. 2021b. Meeting report: 2nd workshop of the peptide ADME Discussion Group. Xenobiotica. 51(1):1–4.
- Sonesson A, Bjørnsdottir I, Christensen JK, Kammersgaard Christensen J. 2021c. Meeting report: 3rd workshop of the peptide ADME Discussion Group. Xenobiotica. 51(12):1470–1474.
- Walles M, Pähler A, Weidolf L, Isin EM. 2021. Meeting report of the first European biotransformation workshop. Xenobiotica. 51(9):1081–1086.
- Walles M, Pähler A, Isin EM, Weidolf L. 2022. Meeting report of the second European biotransformation workshop. Xenobiotica. 52(4):426–431.